When it comes to the development of new medicines and treatments for the healthcare sector, in many cases, the most innovative work is being done by emerging and high-growth pharmaceutical companies. The increase and popularity of biologic medications, for instance, has given small-to-mid-sized pharmaceutical firms in Canada an ability to grow or expand.
For Canada’s emerging and high-growth pharmaceutical companies to succeed in this global industry with increasing competition, they must have continuous access to growth capital, strategies for intellectual property protection and a deep understanding of the regulatory environment. Delays caused by dealing with the complexity of regulatory bodies could allow a competitor to take a similar product to market first.
Osler has a long-standing commitment to supporting emerging and high-growth firms wherever they are in their growth trajectory. With our extensive work at every stage of a company’s life cycle, we are prepared to assist in securing capital, pilot program launches, tax issues, M&A deals or understanding the regulatory complexities of the sector. Our Pharmaceutical, Biotech and Life Sciences Group is also strategically situated in major Canadian research and development hubs in Toronto, Ottawa and Montréal. Thanks to our extensive business network, we can also help clients identify new opportunities.
As this space continues to evolve, the need for innovative high-growth operations will only increase. It’s important to work with a team that understands what you’re going through and can help you succeed.